Overcoming osimertinib resistance in NSCLC: The role of Notch1 pathway inhibition by berberine

Key Points

• Osimertinib resistance can be reduced by inhibiting the notch1 pathway with berberine.
• Key evidence indicates that berberine treatment decreases cancer cell survival by affecting notch1 signaling.
• Observational analysis across NSCLC cell lines shows a significant interaction between berberine and notch1 inhibition.
• This research highlights the potential of berberine as a therapeutic agent against osimertinib resistance in lung cancer.